Cargando…

Differential distribution and prognostic value of CD4(+) T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes

Differentiated thyroid cancer is the most frequently diagnosed endocrine tumor. While differentiated thyroid cancers often respond to initial treatment, little is known about the differences in circulating immune cells amongst patients who respond differently. A prospective study of 39 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Zhi-Yong, Zhang, Sheng-Xiao, Li, Cai-Hong, Fan, Di, Xue, Yan, Cheng, Zhe-Hao, Wu, Li-Xiang, Lu, Ke-Yi, Wu, Zhi-Fang, Li, Xiao-Feng, Liu, Hai-Yan, Li, Si-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459039/
https://www.ncbi.nlm.nih.gov/pubmed/36091039
http://dx.doi.org/10.3389/fimmu.2022.966550
_version_ 1784786414957756416
author Shi, Zhi-Yong
Zhang, Sheng-Xiao
Li, Cai-Hong
Fan, Di
Xue, Yan
Cheng, Zhe-Hao
Wu, Li-Xiang
Lu, Ke-Yi
Wu, Zhi-Fang
Li, Xiao-Feng
Liu, Hai-Yan
Li, Si-Jin
author_facet Shi, Zhi-Yong
Zhang, Sheng-Xiao
Li, Cai-Hong
Fan, Di
Xue, Yan
Cheng, Zhe-Hao
Wu, Li-Xiang
Lu, Ke-Yi
Wu, Zhi-Fang
Li, Xiao-Feng
Liu, Hai-Yan
Li, Si-Jin
author_sort Shi, Zhi-Yong
collection PubMed
description Differentiated thyroid cancer is the most frequently diagnosed endocrine tumor. While differentiated thyroid cancers often respond to initial treatment, little is known about the differences in circulating immune cells amongst patients who respond differently. A prospective study of 39 patients with differentiated thyroid cancer was conducted. Serum thyroglobulin levels and thyroid and immunological functions were tested before and after radioactive iodine treatment (RAIT). Efficacy assessments were performed 6 to 12 months after radioactive iodine treatment. Most patients showed an excellent response to radioactive iodine treatment. Before radioactive iodine treatment, the excellent response group had considerably fewer circulating CD4(+) T cell subsets than the non-excellent response group. Both the excellent response and non-excellent response groups had considerably lower circulating CD4(+) T lymphocyte subsets 30 days after radioactive iodine treatment, but those of the excellent response group were still lower than those of the non-excellent response group. All circulating CD4(+) T cell subsets in the excellent response group rose by varying degrees by the 90th day, but only Treg cell amounts increased in the non-excellent response group. Interestingly, in the non-excellent response group, we noticed a steady drop in Th1 cells. However, the bulk of circulating CD4(+) T cell subsets between the two groups did not differ appreciably by the 90th day. Finally, we discovered that CD4(+) T cell subsets had strong predictive potential, and we thus developed high-predictive-performance models that deliver more dependable prognostic information. In conclusion, in individuals with differentiated thyroid cancer, there is great variation in circulating immune cells, resulting in distinct treatment outcomes. Low absolute CD4(+) T cell counts is linked to improved clinical outcomes as well as stronger adaptive and resilience capacities.
format Online
Article
Text
id pubmed-9459039
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94590392022-09-10 Differential distribution and prognostic value of CD4(+) T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes Shi, Zhi-Yong Zhang, Sheng-Xiao Li, Cai-Hong Fan, Di Xue, Yan Cheng, Zhe-Hao Wu, Li-Xiang Lu, Ke-Yi Wu, Zhi-Fang Li, Xiao-Feng Liu, Hai-Yan Li, Si-Jin Front Immunol Immunology Differentiated thyroid cancer is the most frequently diagnosed endocrine tumor. While differentiated thyroid cancers often respond to initial treatment, little is known about the differences in circulating immune cells amongst patients who respond differently. A prospective study of 39 patients with differentiated thyroid cancer was conducted. Serum thyroglobulin levels and thyroid and immunological functions were tested before and after radioactive iodine treatment (RAIT). Efficacy assessments were performed 6 to 12 months after radioactive iodine treatment. Most patients showed an excellent response to radioactive iodine treatment. Before radioactive iodine treatment, the excellent response group had considerably fewer circulating CD4(+) T cell subsets than the non-excellent response group. Both the excellent response and non-excellent response groups had considerably lower circulating CD4(+) T lymphocyte subsets 30 days after radioactive iodine treatment, but those of the excellent response group were still lower than those of the non-excellent response group. All circulating CD4(+) T cell subsets in the excellent response group rose by varying degrees by the 90th day, but only Treg cell amounts increased in the non-excellent response group. Interestingly, in the non-excellent response group, we noticed a steady drop in Th1 cells. However, the bulk of circulating CD4(+) T cell subsets between the two groups did not differ appreciably by the 90th day. Finally, we discovered that CD4(+) T cell subsets had strong predictive potential, and we thus developed high-predictive-performance models that deliver more dependable prognostic information. In conclusion, in individuals with differentiated thyroid cancer, there is great variation in circulating immune cells, resulting in distinct treatment outcomes. Low absolute CD4(+) T cell counts is linked to improved clinical outcomes as well as stronger adaptive and resilience capacities. Frontiers Media S.A. 2022-08-26 /pmc/articles/PMC9459039/ /pubmed/36091039 http://dx.doi.org/10.3389/fimmu.2022.966550 Text en Copyright © 2022 Shi, Zhang, Li, Fan, Xue, Cheng, Wu, Lu, Wu, Li, Liu and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Shi, Zhi-Yong
Zhang, Sheng-Xiao
Li, Cai-Hong
Fan, Di
Xue, Yan
Cheng, Zhe-Hao
Wu, Li-Xiang
Lu, Ke-Yi
Wu, Zhi-Fang
Li, Xiao-Feng
Liu, Hai-Yan
Li, Si-Jin
Differential distribution and prognostic value of CD4(+) T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes
title Differential distribution and prognostic value of CD4(+) T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes
title_full Differential distribution and prognostic value of CD4(+) T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes
title_fullStr Differential distribution and prognostic value of CD4(+) T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes
title_full_unstemmed Differential distribution and prognostic value of CD4(+) T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes
title_short Differential distribution and prognostic value of CD4(+) T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes
title_sort differential distribution and prognostic value of cd4(+) t cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459039/
https://www.ncbi.nlm.nih.gov/pubmed/36091039
http://dx.doi.org/10.3389/fimmu.2022.966550
work_keys_str_mv AT shizhiyong differentialdistributionandprognosticvalueofcd4tcellsubsetsbeforeandafterradioactiveiodinetherapyindifferentiatedthyroidcancerwithvariedcurativeoutcomes
AT zhangshengxiao differentialdistributionandprognosticvalueofcd4tcellsubsetsbeforeandafterradioactiveiodinetherapyindifferentiatedthyroidcancerwithvariedcurativeoutcomes
AT licaihong differentialdistributionandprognosticvalueofcd4tcellsubsetsbeforeandafterradioactiveiodinetherapyindifferentiatedthyroidcancerwithvariedcurativeoutcomes
AT fandi differentialdistributionandprognosticvalueofcd4tcellsubsetsbeforeandafterradioactiveiodinetherapyindifferentiatedthyroidcancerwithvariedcurativeoutcomes
AT xueyan differentialdistributionandprognosticvalueofcd4tcellsubsetsbeforeandafterradioactiveiodinetherapyindifferentiatedthyroidcancerwithvariedcurativeoutcomes
AT chengzhehao differentialdistributionandprognosticvalueofcd4tcellsubsetsbeforeandafterradioactiveiodinetherapyindifferentiatedthyroidcancerwithvariedcurativeoutcomes
AT wulixiang differentialdistributionandprognosticvalueofcd4tcellsubsetsbeforeandafterradioactiveiodinetherapyindifferentiatedthyroidcancerwithvariedcurativeoutcomes
AT lukeyi differentialdistributionandprognosticvalueofcd4tcellsubsetsbeforeandafterradioactiveiodinetherapyindifferentiatedthyroidcancerwithvariedcurativeoutcomes
AT wuzhifang differentialdistributionandprognosticvalueofcd4tcellsubsetsbeforeandafterradioactiveiodinetherapyindifferentiatedthyroidcancerwithvariedcurativeoutcomes
AT lixiaofeng differentialdistributionandprognosticvalueofcd4tcellsubsetsbeforeandafterradioactiveiodinetherapyindifferentiatedthyroidcancerwithvariedcurativeoutcomes
AT liuhaiyan differentialdistributionandprognosticvalueofcd4tcellsubsetsbeforeandafterradioactiveiodinetherapyindifferentiatedthyroidcancerwithvariedcurativeoutcomes
AT lisijin differentialdistributionandprognosticvalueofcd4tcellsubsetsbeforeandafterradioactiveiodinetherapyindifferentiatedthyroidcancerwithvariedcurativeoutcomes